The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men

Shehzad Basaria, Lauren Collins, Edgar Dillon, Katie Orwoll, Thomas W. Storer, Renee Miciek, Jagadish Ulloor, Anqi Zhang, Richard Eder, Heather Zientek, Gilad Gordon, Syed Kazmi, Melinda Sheffield-Moore, Shalender Bhasin

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background.Concerns about potential adverse effects of testosterone on prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity.Objectives.To evaluate the safety, tolerability, pharmacokinetics, and effects of ascending doses of LGD-4033 administered daily for 21 days on lean body mass, muscle strength, stair-climbing power, and sex hormones.Methods.In this placebo-controlled study, 76 healthy men (21-50 years) were randomized to placebo or 0.1, 0.3, or 1.0 mg LGD-4033 daily for 21 days. Blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and for 5 weeks after intervention.Results.LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups. Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, or QT intervals did not change significantly at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone-binding globulin, high density lipoprotein cholesterol, and triglyceride levels. follicle-stimulating hormone and free testosterone showed significant suppression at 1.0-mg dose only. Lean body mass increased dose dependently, but fat mass did not change significantly. Hormone levels and lipids returned to baseline after treatment discontinuation.Conclusions.LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.

Original languageEnglish (US)
Pages (from-to)87-95
Number of pages9
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Volume68
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Androgen Receptors
Prostate-Specific Antigen
Testosterone
Pharmacokinetics
Placebos
Muscle Strength
Safety
Fats
Hormones
Lipids
Sex Hormone-Binding Globulin
Gonadal Steroid Hormones
Follicle Stimulating Hormone
Aspartate Aminotransferases
Alanine Transaminase
HDL Cholesterol
Half-Life
Prostate
Electrocardiography
Hemoglobins

Keywords

  • Cachexia
  • Function promoting anabolic therapies
  • Sarcopenia
  • SARMs
  • Selective androgen receptor modulators

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. / Basaria, Shehzad; Collins, Lauren; Dillon, Edgar; Orwoll, Katie; Storer, Thomas W.; Miciek, Renee; Ulloor, Jagadish; Zhang, Anqi; Eder, Richard; Zientek, Heather; Gordon, Gilad; Kazmi, Syed; Sheffield-Moore, Melinda; Bhasin, Shalender.

In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 68, No. 1, 01.2013, p. 87-95.

Research output: Contribution to journalArticle

Basaria, S, Collins, L, Dillon, E, Orwoll, K, Storer, TW, Miciek, R, Ulloor, J, Zhang, A, Eder, R, Zientek, H, Gordon, G, Kazmi, S, Sheffield-Moore, M & Bhasin, S 2013, 'The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men', Journals of Gerontology - Series A Biological Sciences and Medical Sciences, vol. 68, no. 1, pp. 87-95. https://doi.org/10.1093/gerona/gls078
Basaria, Shehzad ; Collins, Lauren ; Dillon, Edgar ; Orwoll, Katie ; Storer, Thomas W. ; Miciek, Renee ; Ulloor, Jagadish ; Zhang, Anqi ; Eder, Richard ; Zientek, Heather ; Gordon, Gilad ; Kazmi, Syed ; Sheffield-Moore, Melinda ; Bhasin, Shalender. / The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences. 2013 ; Vol. 68, No. 1. pp. 87-95.
@article{f81551c26dfa4da0a0be276eb038d418,
title = "The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men",
abstract = "Background.Concerns about potential adverse effects of testosterone on prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity.Objectives.To evaluate the safety, tolerability, pharmacokinetics, and effects of ascending doses of LGD-4033 administered daily for 21 days on lean body mass, muscle strength, stair-climbing power, and sex hormones.Methods.In this placebo-controlled study, 76 healthy men (21-50 years) were randomized to placebo or 0.1, 0.3, or 1.0 mg LGD-4033 daily for 21 days. Blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and for 5 weeks after intervention.Results.LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups. Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, or QT intervals did not change significantly at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone-binding globulin, high density lipoprotein cholesterol, and triglyceride levels. follicle-stimulating hormone and free testosterone showed significant suppression at 1.0-mg dose only. Lean body mass increased dose dependently, but fat mass did not change significantly. Hormone levels and lipids returned to baseline after treatment discontinuation.Conclusions.LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.",
keywords = "Cachexia, Function promoting anabolic therapies, Sarcopenia, SARMs, Selective androgen receptor modulators",
author = "Shehzad Basaria and Lauren Collins and Edgar Dillon and Katie Orwoll and Storer, {Thomas W.} and Renee Miciek and Jagadish Ulloor and Anqi Zhang and Richard Eder and Heather Zientek and Gilad Gordon and Syed Kazmi and Melinda Sheffield-Moore and Shalender Bhasin",
year = "2013",
month = "1",
doi = "10.1093/gerona/gls078",
language = "English (US)",
volume = "68",
pages = "87--95",
journal = "Journals of Gerontology - Series A Biological Sciences and Medical Sciences",
issn = "1079-5006",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men

AU - Basaria, Shehzad

AU - Collins, Lauren

AU - Dillon, Edgar

AU - Orwoll, Katie

AU - Storer, Thomas W.

AU - Miciek, Renee

AU - Ulloor, Jagadish

AU - Zhang, Anqi

AU - Eder, Richard

AU - Zientek, Heather

AU - Gordon, Gilad

AU - Kazmi, Syed

AU - Sheffield-Moore, Melinda

AU - Bhasin, Shalender

PY - 2013/1

Y1 - 2013/1

N2 - Background.Concerns about potential adverse effects of testosterone on prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity.Objectives.To evaluate the safety, tolerability, pharmacokinetics, and effects of ascending doses of LGD-4033 administered daily for 21 days on lean body mass, muscle strength, stair-climbing power, and sex hormones.Methods.In this placebo-controlled study, 76 healthy men (21-50 years) were randomized to placebo or 0.1, 0.3, or 1.0 mg LGD-4033 daily for 21 days. Blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and for 5 weeks after intervention.Results.LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups. Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, or QT intervals did not change significantly at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone-binding globulin, high density lipoprotein cholesterol, and triglyceride levels. follicle-stimulating hormone and free testosterone showed significant suppression at 1.0-mg dose only. Lean body mass increased dose dependently, but fat mass did not change significantly. Hormone levels and lipids returned to baseline after treatment discontinuation.Conclusions.LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.

AB - Background.Concerns about potential adverse effects of testosterone on prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity.Objectives.To evaluate the safety, tolerability, pharmacokinetics, and effects of ascending doses of LGD-4033 administered daily for 21 days on lean body mass, muscle strength, stair-climbing power, and sex hormones.Methods.In this placebo-controlled study, 76 healthy men (21-50 years) were randomized to placebo or 0.1, 0.3, or 1.0 mg LGD-4033 daily for 21 days. Blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and for 5 weeks after intervention.Results.LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups. Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, or QT intervals did not change significantly at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone-binding globulin, high density lipoprotein cholesterol, and triglyceride levels. follicle-stimulating hormone and free testosterone showed significant suppression at 1.0-mg dose only. Lean body mass increased dose dependently, but fat mass did not change significantly. Hormone levels and lipids returned to baseline after treatment discontinuation.Conclusions.LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.

KW - Cachexia

KW - Function promoting anabolic therapies

KW - Sarcopenia

KW - SARMs

KW - Selective androgen receptor modulators

UR - http://www.scopus.com/inward/record.url?scp=84871856095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871856095&partnerID=8YFLogxK

U2 - 10.1093/gerona/gls078

DO - 10.1093/gerona/gls078

M3 - Article

C2 - 22459616

AN - SCOPUS:84871856095

VL - 68

SP - 87

EP - 95

JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

SN - 1079-5006

IS - 1

ER -